Lupin Blisovi Fe 1.5/30 Tablets: Crumbling Tablets in Blister Packs
Lupin Pharmaceuticals recalls Blisovi Fe 1.5/30 tablets due to complaints of crumbling tablets when removed from blister packs. This may affect prescription users.
Lower-risk recall
Failed Tablet/Capsule Specifications: Complaints related to crumbling of tablets when popped out of the blister pack.
Contact the company
What happened, in plain English
Lupin Pharmaceuticals is recalling Blisovi Fe 1.5/30 tablets because they can crumble when taken out of the blister pack. This could lead to improper medication delivery and potential safety issues for users. Read more at govinfonow.com/recall/37495-lupin-blisovi-fe-1-5-30-tablets-crumbling-tablets-in.
Source Summary by GovInfoNow · govinfonow.com/recall/37495-lupin-blisovi-fe-1-5-30-tablets-crumbling-tablets-in · Updated October 5, 2026 · FDA enforcement record: FDA #D-0638-2020
Cite this page
“Lupin Blisovi Fe 1.5/30 Tablets: Crumbling Tablets in Blister Packs.” GovInfoNow, updated October 5, 2026. https://govinfonow.com/recall/37495-lupin-blisovi-fe-1-5-30-tablets-crumbling-tablets-in. Based on FDA recall #D-0638-2020 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0638-2020%22&limit=1).
Why it’s dangerous
The tablets can crumble when removed from the blister pack. This may cause the medication to not be delivered properly, potentially affecting the treatment effectiveness.
Who’s affected
Prescription users of Blisovi Fe 1.5/30 tablets who received this specific product. Those with the NDC 68180-866-11 lot number H801227 are most at risk.
How to tell if you have this one
Check for Blisovi Fe 1.5/30 tablets with NDC 68180-866-11 and lot number H801227. These were distributed by Lupin Pharmaceuticals Inc. in Baltimore, MD.
- Brand
Lupin Pharmaceuticals- Category
Drug
What to do — step by step
Check Product Details
Look for the NDC 68180-866-11 and lot number H801227 on the blister pack.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide within the United States” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 10 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Other Lupin Pharmaceuticals recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0638-2020 (December 26, 2019) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0638-2020 to see it in context.
- Plain-language summary written by qwen3:4b on October 5, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.